TOP
TFBS Bioscience and Tottori University Hold Signing Ceremony for Manufacturing Partnership to Commercialize a Next-Generation Cancer Therapeutic Vaccinia Virus
2025-12-26 TFBS Bioscience and Tottori University Hold Signing Ceremony for Manufacturing Partnership to Commercialize a Next-Generation Cancer Therapeutic Vaccinia Virus TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and Tottori University (Headquarters: Tottori City, Tottori Prefecture; hereinafter “Tottori University”) are pleased to announce that they have entered into a manufacturing services agreement for the future development, commercialization, and practical application of FUVAC121, a next-generation vaccinia virus for cancer therapy developed by Professor Takafumi Nakamura and colleagues at the Faculty of Medicine, Tottori University (hereinafter, the “Partnership”). The signing ceremony was held on December 22, 2025, at the Tottori Campus of Tottori University. Learn more
TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment
2025-12-08 TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan, hereinafter "TFBS") and the National University Tottori University (Headquarters: Tottori City, Tottori Prefecture, Japan, hereinafter "Tottori University") have entered into a business alliance (hereinafter, "the Alliance") regarding the manufacturing of the next-generation vaccinia virus, FUVAC121, developed by Professor Takafumi Nakamura and his team at the Faculty of Medicine, Tottori University. The Alliance aims to advance the future development, commercialization, and practical application of FUVAC121. Learn more
-去背.png){kind=logo}
2025-12-26 TFBS Bioscience and Tottori University Hold Signing Ceremony for Manufacturing Partnership to Commercialize a Next-Generation Cancer Therapeutic Vaccinia Virus TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and Tottori University (Headquarters: Tottori City, Tottori Prefecture; hereinafter “Tottori University”) are pleased to announce that they have entered into a manufacturing services agreement for the future development, commercialization, and practical application of FUVAC121, a next-generation vaccinia virus for cancer therapy developed by Professor Takafumi Nakamura and colleagues at the Faculty of Medicine, Tottori University (hereinafter, the “Partnership”). The signing ceremony was held on December 22, 2025, at the Tottori Campus of Tottori University. Learn more 
2025-12-08 TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan, hereinafter "TFBS") and the National University Tottori University (Headquarters: Tottori City, Tottori Prefecture, Japan, hereinafter "Tottori University") have entered into a business alliance (hereinafter, "the Alliance") regarding the manufacturing of the next-generation vaccinia virus, FUVAC121, developed by Professor Takafumi Nakamura and his team at the Faculty of Medicine, Tottori University. The Alliance aims to advance the future development, commercialization, and practical application of FUVAC121. Learn more 
2025-08-28 artiCure and TFBS Bioscience Join Forces in Virus Manufacturing to Advance Development of Innovative Cancer Gene Therapy Korea’s innovative cancer therapy company artiCure and leading viral vector manufacturer from Taiwan, TFBS Bioscience Inc. jointly announce the collaboration on GMP manufacturing of retroviral vectors, aiming to accelerate clinical trials of cancer gene therapy in Korea. Learn more 
2025-08-28 TFBS Bioscience and U-Medico Announce Strategic Alliance to Launch GMP QC Testing Services for CGT therapeutics TFBS Bioscience Inc., a Taiwan and Japan-based company offering total solutions for GMP manufacturing of viral vector and U-Medico Inc., a leading Japanese company providing advanced analytical solutions, today announced a strategic partnership to jointly launch a new suite of Good Manufacturing Practice (GMP) Quality Control (QC) testing services. This collaboration marks a significant milestone in international cooperation, aiming at delivering accurate, regulatory-compliant QC testing services for viral vectors across Japan, Taiwan, and the broader Asia-Pacific region. Learn more 